Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, placebo-controlled, parallel group trial of atomoxetine (1.8
mg/kg) for the management of chemotherapy-related acquired attentional disorders in children
who have survived Acute Lymphocytic Leukemia. Atomoxetine will produce a favorable impact on
ADHD symptoms in children with chemo-related acquired attentional disorders.